Developments in RNA therapies and technologies

Companies that have pioneered platforms based on oligonucleotides targeting RNA and their biopharma partners continue to move beyond rare diseases into broader patient populations with cardiovascular diseases and central nervous system disorders.

Philadelphia’s Aro Biotherapeutics has developed a novel RNA platform that leverages Centyrin proteins to deliver oligonucleotides to muscle and immune cells.

Cancer Research Horizons (CRH) is harnessing the skills, expertise, and research network of its parent organization to speed-up the discovery and development of transformative oncology drugs, improve patient outcomes, and advance assets for biopharma partners.

Unique proteolipid vehicle (PLV) technology developed by Entos Pharmaceuticals is broadening the scope for biopharma to deliver nucleic-acid payoffs to target cells throughout the body, paving the way for a new generation of curative drugs.

Primrose Bio’s advanced technology for manufacturing nucleic acids and proteins makes it the partner of choice for pharma companies developing new vaccines, therapeutics and bio-based products.

Through its innovative asymmetric siRNA platforms, OliX Pharmaceuticals is opening up huge opportunities in RNA interference-therapeutic development to address unmet needs for various indications spanning the liver, eye, skin, and beyond.

Azor Biotek is applying artificial intelligence solutions to the design and development of tailored, highly specific, novel small molecules, tapping into the vast potential of RNA drug targets.

Visionary investment in mRNA technology platforms is allowing ST PHARM and its two startups, Levatio Therapeutics and Vernagen, to foster partnerships and advance the development of cutting-edge RNA-based drugs and vaccines.

Genialis is the RNA biomarker company; it espouses a people-first approach to machine learning–driven biomarker discovery. For targeted therapies to benefit the most patients possible, Genialis develops predictive biomarkers to guide treatment decisions. The company’s next-generation biomarkers work for real patients by informing targeted treatment decisions for better outcomes.